A specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction

Dennis Urbaniak appointed EVP Digital Health

DECEMBER 2, 2019 - Orexo strengthen its competencies within digital health, by appointing Dennis Urbaniak as EVP for Digital Health. Dennis has had a long, successful career within the life sciences industry and during the last years become one of the leading experts in digital health in the US. At Orexo Dennis will have an instrumental role in the work to find innovative digital solutions to improve treatment of addiction.

Orexo acquires exclusive US rights to commercialize vorvida®

NOVEMBER 27, 2019 – In line with the ambition to become a leader within treatment of addiction the company today has extended its partnership with GAIA AG by in-licensing of the US commercial rights to vorvida®, a digital therapy for the treatment of Alcohol Use Disorder (AUD). Vorvida® is a fully automated digital therapy with significantly proven efficacy to reduce troublesome drinking patterns in adults with AUD.

Save the Date – Capital Markets Day focusing on Digital Health

Investors, analysts and media are invited to attend our Capital Markets Day that will take place at, Helio GT 30, Grev Turegatan 30, Stockholm, Sweden. The program will start at 1:30 pm CET, with registration from 1:00 pm CET. The event plans to end at 4.00 pm CET. A formal invitation with a complete program will be sent out at a later date. #strategy #pipeline #digitalhealth

Our CEO about entering Digital Therapies

AUGUST 21, 2019 - Orexo will together with its partner GAIA AG develop and commercialize a new digital therapy to increase access and improve treatments of Opioid Use Disorder. Why digital therapies, why now and why together with GAIA? Nikolaj Sørensen, CEO, answers this questions in the latest version of Orexo Our View.